Origin and immunoescape of uterine cervical cancer

[en] Human papillomavirus associated uterine cervical cancer is an important public health problem since it is classified as the fourth most common cancer in women worldwide with more than 500 000 recorded cases. This review is focused on where and why HPV infection induces cervical cancers and how this virus avoids the host immune response. Immunological therapeutic approaches are also addressed.

Research Center/Unit :

GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège
d‐BRU - Dental Biomaterials Research Unit - ULiège

Disciplines :

Biochemistry, biophysics & molecular biology
Anatomy (cytology, histology, embryology...) & physiology

Author, co-author :

Van hede, Dorien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Virologie

Langers, Inge ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Virologie

DELVENNE, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

Jacobs, Nathalie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Virologie

Language :

English

Title :

Origin and immunoescape of uterine cervical cancer

Publication date :

04 November 2014

Journal title :

Presse Médicale

ISSN :

0755-4982

eISSN :

2213-0276

Publisher :

Elsevier, France

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique

Available on ORBi :

since 19 November 2014

Statistics

Number of views

93 (12 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Forouzanfar M.H., Foreman K.J., Delossantos A.M., et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-1484.
Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
Burghardt E., Ostor A.G. Site and origin of squamous cervical cancer: a histomorphologic study. Obstet Gynecol 1983, 62:117-127.
Bernard H.U., Burk R.D., Chen Z., et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
Clifford G.M., Smith J.S., Plummer M., et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
Plummer M., Schiffman M., Castle P.E., et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195:1582-1589.
Bzhalava D., Guan P., Franceschi S., et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013, 445:224-231.
de Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology 2013, 445:2-10.
Bouvard V., Baan R., Straif K., et al. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009, 10:321-322.
zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009, 384:260-265.
Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agents Cancer 2009, 4:8.
Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
Ellerbrock T.V., Chiasson M.A., Bush T.J., et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000, 283:1031-1037.
Cancer ICoESoC Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2005, 118:1481-1495.
Delvenne P., Herman L., Kholod N., Caberg J., Herfs M., Boniver J., et al. Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. Mol Cell Endocrinol 2007, 264:1-5.
Marsh M. Original site of cervical carcinoma; topographical relationship of carcinoma of the cervix to the external os and to the squamocolumnar junction. Obstet Gynecol 1956, 7:444-452.
Howard L., Erickson C.C., Stoddard L.D. A study of the incidence and histogenesis of endocervical metaplasia and intraepithelial carcinoma; observations on 400 uteri removed for non-cervical disease. Cancer 1951, 4:1210-1223.
Beclere C. Cancer du col de l'utérus d'origine intra-cervicale. Gynecol Prat 1954, 5:297-308.
Smedts F., Ramaekers F., Troyanovsky S., et al. Keratin expression in cervical cancer. Am J Pathol 1992, 141:497-511.
Larson A.A., Liao S.Y., Stanbridge E.J., et al. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res 1997, 57:4171-4176.
zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986, 2:489-491.
Herfs M., Yamamoto Y., Laury A., et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012, 109:10516-10521.
Phelps W.C., Howley P.M. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J Virol 1987, 61:1630-1638.
Woodman C.B., Collins S.I., Young L.S. The natural history of cervical HPV infection: unresolved issues. Nature reviews. Cancer 2007, 7:11-22.
Doorbar J., Quint W., Banks L., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30:F55-F70.
Heck D.V., Yee C.L., Howley P.M., et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992, 89:4442-4446.
Li X., Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996, 70:4509-4516.
Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993, 13:4918-4927.
Scheffner M., Huibregtse J.M., Vierstra R.D., et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
Gewin L., Myers H., Kiyono T., et al. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004, 18:2269-2282.
Nguyen M.L., Nguyen M.M., Lee D., et al. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 2003, 77:6957-6964.
Lee S.S., Weiss R.S., Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94:6670-6675.
Nakagawa S., Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 2000, 20:8244-8253.
Pim D., Thomas M., Javier R., et al. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 2000, 19:719-725.
Shinyo Y., Kodama J., Hongo A., et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003, 14:1505-1510.
Zeng C., Ke Z.F., Luo W.R., et al. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med Oncol 2013, 30:403.
Hirshoren N., Bulvik R., Neuman T., et al. Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med 2014, 18:181-186.
Arvatz G., Shafat I., Levy-Adam F., et al. The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev 2011, 30:253-268.
Williams V.M., Filippova M., Filippov V., et al. HPV16 E6* induces oxidative stress and DNA damage. J Virol 2014, 88:6751-6761.
Demers G.W., Espling E., Harry J.B., et al. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 1996, 70:6862-6869.
Zerfass K., Levy L.M., Cremonesi C., et al. Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. J Gen Virol 1995, 76:1815-1820.
Wang N., Zhan T., Ke T., et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer 2014, 110:1034-1044.
Zerfass-Thome K., Zwerschke W., Mannhardt B., et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996, 13:2323-2330.
Funk J.O., Waga S., Harry J.B., et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997, 11:2090-2100.
Fan X., Liu Y., Heilman S.A., et al. Human papillomavirus E7 induces rereplication in response to DNA damage. J Virol 2013, 87:1200-1210.
Pim D., Collins M., Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992, 7:27-32.
Straight S.W., Hinkle P.M., Jewers R.J., et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993, 67:4521-4532.
Tomakidi P., Cheng H., Kohl A., et al. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur J Cell Biol 2000, 79:407-412.
Zhang B., Srirangam A., Potter D.A., et al. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005, 24:2585-2588.
Kim S.H., Oh J.M., No J.H., et al. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30:753-757.
Kivi N., Greco D., Auvinen P., et al. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 2008, 27:2532-2541.
Jackson S., Harwood C., Thomas M., et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000, 14:3065-3073.
Garnett T.O., Filippova M., Duerksen-Hughes P.J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006, 13:1915-1926.
Katzenellenbogen R.A., Egelkrout E.M., Vliet-Gregg P., et al. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J Virol 2007, 81:3786-3796.
Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nature reviews. Cancer 2002, 2:59-65.
Fruchter R.G., Maiman M., Sedlis A., et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996, 87:338-344.
Abramowitz L., Benabderrahmane D., Ravaud P., et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 2007, 21:1457-1465.
Buck C.B., Day P.M., Thompson C.D., et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006, 103:1516-1521.
Amador-Molina A., Hernandez-Valencia J.F., Lamoyi E., et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013, 5:2624-2642.
Denis M., Chadee K., Matlashewski G.J. Macrophage killing of human papillomavirus type 16-transformed cells. Virology 1989, 170:342-345.
Hubert P., Giannini S.L., Vanderplasschen A., et al. Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. FASEB J 2001, 15:2521-2523.
Renoux V.M., Bisig B., Langers I., et al. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 2011, 41:3240-3252.
Reschner A., Hubert P., Delvenne P., et al. Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin Exp Immunol 2008, 152:219-226.
Langers I., Renoux V.M., Thiry M., et al. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012, 6:73-82.
Lee S.J., Cho Y.S., Cho M.C., et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001, 167:497-504.
Molling J.W., de Gruijl T.D., Glim J., et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007, 121:1749-1755.
de Jong A., van der Burg S.H., Kwappenberg K.M., et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002, 62:472-479.
Welters M.J., de Jong A., van den Eeden S.J., et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003, 63:636-641.
Bourgault Villada I., Moyal Barracco M., Berville S., et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010, 159:45-56.
Nishimura H., Yajima T., Kagimoto Y., et al. Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2. J Virol 2004, 78:4927-4930.
Ogra P.L., Yamanaka T., Losonsky G.A. Local immunologic defenses in the genital tract. Prog Clin Biol Res 1981, 70:381-394.
Nicholls P.K., Klaunberg B.A., Moore R.A., Santos E.B., Parry N.R., Gough G.W., et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999, 265:365-374.
Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999, 9:423-430.
Giannini S.L., Hubert P., Doyen J., et al. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002, 97:654-659.
Giannini S.L., Al-Saleh W., Piron H., et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998, 113:183-189.
Herfs M., Hubert P., Kholod N., et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol 2008, 172:1391-1402.
Karim R., Meyers C., Backendorf C., et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011, 6. 6:e17848.
Kanodia S., Fahey L.M., Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007, 7:79-89.
Hasan U.A., Zannetti C., Parroche P., et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 2013, 210:1369-1387.
Ronco L.V., Karpova A.Y., Vidal M., et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12:2061-2072.
Li S., Labrecque S., Gauzzi M.C., et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18:5727-5737.
Quatromoni J.G., Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012, 4:376-389.
Goncalves M.A., Soares E.G., Fernandes A.P., et al. Langerhans' cell count and HLA class II profile in cervical intraepithelial neoplasia in the presence or absence of HIV infection. Eur J Obstet Gynecol Reprod Biol 2004, 114:221-227.
Matthews K., Leong C.M., Baxter L., et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003, 77:8378-8385.
Caberg J.H., Hubert P.M., Begon D.Y., et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008, 29:1441-1447.
Fausch S.C., Da Silva D.M., Rudolf M.P., et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002, 169:3242-3249.
Da Silva D.M., Fausch S.C., Verbeek J.S., et al. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007, 178:7587-7597.
Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
Bolpetti A., Silva J.S., Villa L.L., et al. Interleukin-10 production by tumor infiltrating macrophages plays a role in human papillomavirus 16 tumor growth. BMC Immunol 2010, 11:27.
Lepique A.P., Daghastanli K.R., Cuccovia I.M., et al. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009, 15:4391-4400.
Ashrafi G.H., Haghshenas M., Marchetti B., et al. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006, 119:2105-2112.
Arends J.W., Groniowski M.M., de Koning Gans H.J., et al. Immunohistochemical study of the distribution of secretory component and IgA in the normal and diseased uterine mucosa. Int J Gynecol Pathol 1983, 2:171-181.
Lowy D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest 2006, 116:1167-1173.
Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
Drolet M., Laprise J.F., Boily M.C., et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014, 134:2264-2268.
Ma B., Maraj B., Tran N.P., et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012, 17:469-492.
Vambutas A., DeVoti J., Nouri M., et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005, 23:5271-5280.
van Poelgeest M.I., Welters M.J., van Esch E.M., et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013, 11:88.
Hubert P., Doyen J., Capelle X., et al. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions. Am J Reprod Immunol 2010, 64:126-136.
Zhang J., Li S., Yan Q., et al. Interferon-beta induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One 2013, 8:e81366.
Wang Z., Wakae K., Kitamura K., et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol 2014, 88:1308-1317.
Chiantore M.V., Vannucchi S., Accardi R., et al. Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One 2012, 7:e36909.
Scholten K.B., Turksma A.W., Ruizendaal J.J., et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med 2011, 9:147.
Cuburu N., Graham B.S., Buck C.B., et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012, 122:4606-4620.
Accardi L., Paolini F., Mandarino A., et al. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer 2014, 134:2742-2747.